Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)

  Print   

Thursday 03 June, 2021

Tissue Regenix Group

Result of AGM

RNS Number : 7644A
Tissue Regenix Group PLC
03 June 2021
 

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

 

Result of AGM

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that at the AGM held earlier today, all resolutions were duly passed.

 

The results of the poll are set out below:

 

Resolution

 

In favour

%

Against

%

Withheld

1

Ordinary

3,399,235,541

100

0

0

546,855 

2

Ordinary

3,399,212,980

99.99 

76,421 

0.01 

569,416 

3

Ordinary

3,399,212,980

99.99 

76,421 

0.01 

569,416 

4

Ordinary

3,399,656,835

99.99 

16,274 

0.01 

125,561 

5

Ordinary

3,399,656,835

99.99 

74,846 

0.01 

125,561 

6

Ordinary

3,399,656,835

99.99 

16,274 

0.01 

125,561 

7

Ordinary

3,399,656,835

99.99 

17,849 

0.01 

125,561 

8

Ordinary

3,399,338,541

99.99 

194,449 

0.01 

443,855 

9

Ordinary

3,399,338,541

99.99 

17,849 

0.01 

443,855 

10

Ordinary

3,397,632,396

99.90 

3,420,838 

0.10 

2,150,000 

11

Special

3,397,632,396

99.31 

23,283,587 

0.69 

2,150,000 

12

Special

3,399,782,396

99.88 

4,162,711 

0.12 

0

 

NB: Percentage of Votes cast excludes Withheld votes

 

The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 28 April 2021.

 

 

For more information:

 

Tissue Regenix Group plc

David Cocke, Chief Financial Officer

www.tissueregenix.com

Via Walbrook PR

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Ben Maddison / Alex Price

Tel:  +44(0)20 7710 7600

 

Walbrook PR Ltd

Alice Woodings / Paul McManus

Tel: +44 (0)20 7933 8780

         [email protected]

 

 

About Tissue Regenix ( www.tissueregenix.com )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

 

The information contained in this notification is disclosed in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018. The notification form is set out below.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSSDFEDEFSEDM

a d v e r t i s e m e n t